Ischemic Stricture of Intestine Clinical Trial
— ImpACT-1Official title:
Implant for Augmentation of Cerebral Blood Flow Trial-1. A Pilot Study Evaluating the Safety and Effectiveness of the Ischemic Stroke System for Treatment of Acute Ischemic Stroke
| NCT number | NCT03733236 |
| Other study ID # | CLP1000450 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | July 6, 2006 |
| Est. completion date | January 2009 |
| Verified date | November 2018 |
| Source | BrainsGate |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The primary objective of this pilot study is the assessment of the safety of the ISS500
System in patients who have experienced an acute ischemic stroke within the anterior
circulation.
The secondary objectives of this study are to examine the effectiveness of the ISS500 System
implantation in the treatment of acute ischemic stroke.
| Status | Completed |
| Enrollment | 98 |
| Est. completion date | January 2009 |
| Est. primary completion date | January 2009 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 85 Years |
| Eligibility |
Inclusion Criteria: 1. Age: = 18 years and = 85 of both genders 2. Patients with symptoms and signs of an acute ischemic hemispheric stroke within the anterior circulation. 3. NIHSS = 7 and = 20 4. Treatment can be initiated within the first 24 hours following stroke onset or since last seen normal. 5. Signed informed consent has been obtained from the patient him/herself or his/her legally authorized representative Exclusion Criteria: 1. Time interval since onset of symptoms undetermined 2. Treatment with ISS500 System can't start within the first 24 hours post stroke onset 3. Any other imaging diagnosis including tumor, abscess, primary intracranial hemorrhage (ICH) or secondary hemorrhage (PH1-PH2) (H1 and H2 are allowed); or symptoms suspicious for sub-arachnoid hemorrhage, etc 4. Clinical syndrome of an acute stroke due to lacunar infarct (pure motor hemiparesis, ataxic hemiparesis, sensorimotor stroke), unless brain imaging demonstrates a relevant lesion > 1.5 cm in size 5. Not a stroke in the anterior circulation 6. Minor stroke with non-disabling deficit or rapidly improving neurological symptoms with a high probably to Transient Ischemic Attack (TIA) 7. Eligible to or treated with IV or IA t-PA or mechanical thrombolysis 8. Baseline NIHSS >20 or < 7 9. Neurological deficit that has led to stupor or coma (NIHSS level of consciousness score greater than or equal to 2) 10. History of stroke in previous 6 months 11. Pre-existing disability; Modified Rankin Score > 2 upon screening 12. Patients under oral anticoagulants or having received heparin within 48 hours, and / or with elevated activated partial thromboplastin time (aPTT) (or INR) 13. High clinical suspicion of septic embolus 14. Severe cardiac disease: evidence of congestive heart failure or has history of endstage cardiovascular disease (e.g. CHF NYHA Class III or IV or unstable angina) 15. Uncontrolled hypertension upon enrollment (systolic >185 mmHg and/or diastolic >110 mmHg) 16. Serious systemic infection 17. Women known to be pregnant or having a positive or indeterminate pregnancy test 18. Patients with other implanted neural stimulator 19. Orthodontics or non-Hygienic condition/ problems that prevent procedures within the mouth 20. MRI2 contraindications, such as but not limited to: - Central nervous system aneurysm clips - Implanted cardiac pacemaker or defibrillator; - Cochlear implant - Ocular foreign body (e.g. metal shavings) - Insulin pump - Metal shrapnel or bullet - Any implanted device that is incompatible with MRI. - Patients with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, etc.) 21. Life expectancy < 1 year from other causes 22. Currently participating in any other clinical trial 23. Patients unable or unwilling to follow protocol requirements 24. Massive stroke, defined as acute parenchymal hypodense lesion or effacement of cerebral sulci in over a 2/3 of the MCA territory per CT (or equivalent per T2/Flair/DWI MRI) |
| Country | Name | City | State |
|---|---|---|---|
| India | Postgraduate Institute of Medical Education and Research | Chandigarh | |
| India | Nizam's Institute of Medical Research Punjagutta, Hyderabad. | Hyderabad |
| Lead Sponsor | Collaborator |
|---|---|
| BrainsGate |
India,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Patient and treatment compliance to the stimulation | The ability to maintain treatment in each session for the treatment length, and the compliance for the whole treatment period; i.e. each treatment session should be performed for at least 85% of the prescribed regimen | 5 Days | |
| Primary | Treatment successful completion | The need to stop the treatment sessions completely or alternately. | 5 Days | |
| Primary | Adverse Events profile at 90 Day compared to VISTA trials data | Adverse Events profile at 90 days post implantation will be compared to the data retrieved form the VISTA trials. | 90 Days | |
| Secondary | The distribution of modified Rankin scale scores at 90 days | Shift in the distribution of modified Rankin Scale (mRS) scores at 90 days Favorable outcome is mRS score between 0 and 2 | 90 Days | |
| Secondary | NIHSS scores at 90 days | The distribution of total NIHSS scores at 90 days - binary NIHSS (defined as the proportion of favorable outcomes assessed using the NIHSS scale, where as favorable outcome was a complete recovery (NIHSS 0 or 1) or an improvement by 9 or more points in the NIHSS score | 90 Days | |
| Secondary | Proportion of patients achieving a Barthel index at 90 days | The proportion of patients achieving a Barthel index of 95-100 (versus 0-90) at 90 days | 90 Days |